Please assess the completion status of the following clinical trial:

Trial Title: Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-75 years at the time of signing the informed consent form.~* Have been diagnosed as having active rheumatoid arthritis (RA) according to The European League Against Rheumatism criteria~* moderately to severely active RA for at least six months~* Patients who have an inadequate response to the treatment with the usual non-biological regimen for at least 12 weeks according to their investigator judgment.~* Ability to comprehend and willingness to sign the Informed Consent Form for this study.~Exclusion Criteria:~* Tuberculosis patient or latent tuberculosis patient (PPD \>5mm or abnormal Chest X-ray)~* Have been treated previously with any biological agents including any tumor necrosis factor inhibitors (including ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), SIMPONI® (golimumab), or Adalimumab).~* Have a known hypersensitivity to human immunoglobulin proteins or other components of Humira or test- Adalimumab~* Women who are pregnant, breastfeeding or planning to become pregnant during the study~* Have a positive serological test for hepatitis B or hepatitis C or have a known history of infection with human immunodeficiency virus (HIV) of the past three months.~* Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound)~* Have had a serious infection or have been treated with intravenous antibiotics for an infection within eight weeks or oral antibiotics within two weeks prior to screening~* Have a history of chronic or recurrent infection~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> two times upper limit of normal.~* Hemoglobin \<8.5 g/dL.~* Platelets \<125,000/µL.~* Leukocyte count \<3500/µL.~* Serum Creatinine\>2 mg/dl~* Concomitant use of Prednisolone \> 10 mg/day and NSAIDs~* Treatment with intravenous, intramuscular, intra-articular and oral corticosteroids within four weeks prior to Day 1 (prednisolone, more than 7.5 mg/daily)~* Ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).~* Have any of the following conditions:~  1. History of congestive heart failure.~ 2. History of acute myocardial infarction or unstable angina within the previous 12 months prior to Screening.~ 3. History of demyelinating disorders (e.g., MS)~ 4. History of multiple sclerosis~ 5. History of any malignancy within the previous five years prior to Screening.~ 6. Any other disease or disorder which, in the opinion of the Investigator, will put the subject at risk if they are enrolled.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CinnaGen adalimumab (Type: EXPERIMENTAL): CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
- AbbVie adalimumab (Type: ACTIVE_COMPARATOR): Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.

Based on this trial design, predict the completion outcome and termination type (if applicable).